 In 2018, the founder of Bicycle Therapeutics NASDAQ: BCYC, Sir Gregory Winter, was awarded the Nobel Prize in chemistry for his work in developing phage display use of viruses that infect bacteria to connect proteins to produce antibodies and peptides small chains of amino acids for new medicine. The work that won the prize involves the foundation of the companys namesake technology for combating various oncological and ophthalmological conditions, bicycles, which are a combination of two circular peptide chains that possess clinical properties. Can the company deliver wealth for shareholders by developing new medicines via bicycles? 